FDA Approves First Cell-Based Gene Therapy for Adult Patients …
WEBMar 27, 2021 · The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose...
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma …
WEBApr 5, 2024 · Abecma is now approved in the U.S., Japan, Switzerland and the EU for earlier use for triple-class exposed relapsed and/or refractory multiple myeloma, underscoring BMS’ commitment to delivering Abecma globally, with consistently high manufacturing success rates and continuous increases in capacity.
Citing enrollment challenges, Bristol Myers and 2seventy scrap Abecma …
WEB5 days ago · Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial.
Bristol Myers Squibb - Bristol Myers Squibb’s Abecma …
WEBMar 20, 2024 · Abecma is the first chimeric antigen receptor (CAR) T cell immunotherapy approved in the European Union (EU) for use in earlier lines of therapy for relapsed and refractory multiple myeloma. This expanded approval of Abecma covers all EU member states.* In the EU, Abecma has maintained its Orphan Designation for the treatment of multiple myeloma.
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEBMar 26, 2021 · Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma1. In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and …
Abecma Delivers Sustained Progression-Free Survival Versus …
WEBDec 12, 2023 · Abecma is the first-in-class B-cell maturation antigen (BCMA)-directed CAR T cell immunotherapy approved by the FDA for the treatment of adult patients with relapsed or refractory multiple...
FDA Approves Abecma for RRMM | Int'l Myeloma Foundation
WEBApr 5, 2024 · This press release covers the FDA-approval of Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly ...
WEB4 days ago · 2seventy bio, Inc (NASDAQ:TSVT) and its partner Bristol Myers Squibb & Co (NYSE:BMY), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma (idecabtagene vicleucel; ide-cel...
2seventy, Bristol Myers Drop Abecma Study in Newly
WEB5 days ago · 2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma.
Abecma hits the mark in earlier-stage multiple myeloma
WEBAug 11, 2022 · BMS and 2Seventy have revealed that Abecma achieved an improvement compared to standard care on progression-free survival (PFS), and say they now plan to submit the trial data quickly to...